Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment

Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment

Abstract Background The introduction of adjuvant therapies for patients with resected cutaneous melanoma (CM) has increased the need for sensitive biomarkers for risk stratification and disease monitoring. This study aims to investigate the utility of circulating tumor DNA (ctDNA) assessment in pred...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara Marchisio, Alessia Andrea Ricci, Gabriele Roccuzzo, Eleonora Bongiovanni, Erika Ortolan, Luca Bertero, Enrico Berrino, Valentina Pala, Renata Ponti, Paolo Fava, Simona Osella-Abate, Silvia Deaglio, Caterina Marchiò, Anna Sapino, Rebecca Senetta, Ada Funaro, Simone Ribero, Pietro Quaglino, Paola Cassoni
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Journal of Translational Medicine
Subjects:
Liquid biopsy
ddPCR
Cutaneous melanoma
Disease monitoring
Adjuvant therapy
Online Access:https://doi.org/10.1186/s12967-024-05783-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items